Advanced Therapy Medicinal Products (ATMPs) are at the cutting edge. The profit potential is enormous, as is the potential benefit for patients with now-untreatable or incurable conditions.
But as anyone who’s been there knows, the cutting edge can be a cold and dicey place.
Angela Pitwood, VP-Pharmacovigilance at Vigilare International, a WIRB Copernicus Group (WCG) subsidiary, has spent years working with all types of products both in clinical development and post approval. She can share with you the best ways to meet compliance for products used in personalized medicine.
This FREE webinar features an hour with Ms. Pitwood:
ATMPs promise a bounty of new profits for drug and biotech makers … and a host of headaches on the road to that goal. This FREE sponsored webinar offers an edge in a competitive new area. Sign up now!
Who Will Benefit
Biotech companies with ATMPs or companies partnering with the innovator of therapies such as gene therapy medicinal products (GTMPs), somatic cell therapy medicinal products and tissue-engineered products. Specific job responsibilities include:
Sign Up for FREE Below
Vice President of Pharmacovigilance
Angela Pitwood, Vice President of Pharmacovigilance at Vigilare, has spent years on the firing line of combination product post-market reporting and compliance. She’ll share with you her secrets and tips for compliance with the Final Rule so you can avoid legal hot water.